ZX-4081 / Zenshine Pharmaceuticals - LARVOL DELTA

A phase 1 study of selective PI3Kγ inhibitor ZX-4081 in patients with advanced solid tumors (AACR 2022) - P1 | "Its absorption, distribution, metabolism, and excretion (ADME) and safety profile, through a series of in vitro and in vivo studies, support the clinical development of ZX-4081. Inclusion of combination therapy is planned after obtaining the initial clinical assessment of ZX-4081 on its safety, tolerability, pharmacokinetics, and pharmacodynamics."

Clinical • P1 data • Oncology • Solid Tumor • CD8 • MRC1 • PIK3CG

Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Nanjing Zenshine Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck